Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients

European Urology

Volumn 62, Issue 4, 2012, Pages 685-695

  Vermaat, Joost S ^a   Gerritse, Frank L ^a   Van Der Veldt, Astrid A ^b   Roessingh, Wijnand M ^a   Niers, Tatjana M ^c   Oosting, Sjoukje F ^d   Sleijfer, Stefan ^e   Roodhart, Jeanine M ^a   Beijnen, Jos H ^f,g   Schellens, Jan H ^f,g   Gietema, Jourik A ^d   Boven, Epie ^b   Richel, Dick J ^c   Haanen, John B ^f   Voest, Emile E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^g UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Metastatic renal cell cancer patients; Overall survival; Prognostication; Progression free survival; Serum amyloid

Indexed keywords

ANGIOSTATIN; APOLIPOPROTEIN A2; BEVACIZUMAB; CEDIRANIB; EVEROLIMUS; INTERLEUKIN 2; INTERLEUKIN 6 ANTIBODY; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; SERUM AMYLOID A; SORAFENIB; SUNITINIB; TELATINIB; TEMSIROLIMUS;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84861505333     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.01.020     Document Type: Article

References (38)

1. R.J. Motzer, J. Bacik, B.A. Murphy, P. Russo, and M. Mazumdar Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296
2. K. Gupta, J.D. Miller, J.Z. Li, M.W. Russell, and C. Charbonneau Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review Cancer Treat Rev 34 2008 193 205
3. G. Di Lorenzo, R. Autorino, and C.N. Sternberg Metastatic renal cell carcinoma: recent advances in the targeted therapy era Eur Urol 56 2009 959 971
4. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
5. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
6. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
7. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
8. R.J. Motzer, B. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
9. B.I. Rini Metastatic renal cell carcinoma: many treatment options, one patient J Clin Oncol 27 2009 3225 3234
10. A. Bex, E. Jonasch, and Z. Kirkali Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials Eur Urol 58 2010 819 828
11. J.-J. Patard, G. Pignot, and B. Escudier ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease Eur Urol 60 2011 684 690
12. R.J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, and J. Ferrara Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
13. T.M. Mekhail, R.M. Abou-Jawde, and G. Boumerhi Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma J Clin Oncol 23 2005 832 841
14. M.B. Atkins, T.K. Choueiri, D. Cho, M. Regan, and S. Signoretti Treatment selection for patients with metastatic renal cell carcinoma Cancer 115 Suppl 2009 2327 2333
15. B. Escudier, L. Albiges, A. Blesius, Y. Loriot, C. Massard, and K. Fizazi How to select targeted therapy in renal cell cancer Ann Oncol 7 Suppl 2010 vii59 vii62
16. G.R. Hudes, M.A. Carducci, and T.K. Choueiri NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy J Natl Compr Canc Netw 1 Suppl 2011 S1 S29
17. R.J. Motzer, N. Agarwal, and C. Beard Kidney cancer J Natl Compr Canc Netw 9 2011 960 977
18. A. Bamias, A. Karadimou, and S. Lampaki Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model BMC Cancer 10 2010 45
19. F. Donskov, and M.H. von der Impact of immune parameters on long-term survival in metastatic renal cell carcinoma J Clin Oncol 24 2006 1997 2005
20. S. Patil, R.A. Figlin, and T.E. Hutson Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma Ann Oncol 22 2011 295 300
21. J. Manola, P. Royston, and P. Elson Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group Clin Cancer Res 17 2011 5443 5450
22. J.S. Vermaat, I. van der Tweel, and N. Mehra Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models Ann Oncol 21 2010 1472 1481
23. D.Y. Heng, W. Xie, and G.A. Bjarnason Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy Cancer 117 2011 2637 2642
24. R.J. Motzer, R.M. Bukowski, and R.A. Figlin Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma Cancer 113 2008 1552 1558
25. P.I. Karakiewicz, M. Sun, J. Bellmunt, V. Sneller, and B. Escudier Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria Eur Urol 60 2011 48 56
26. F.E. Harrell Regression modeling strategies with applications to linear models, logistic regression, and survival analysis 2001 Springer New York, NY
27. H. Akaike Information theory and an extension of the maximum likelihood principle 1973 Akademiai Kaiado Budapest, Hungary
28. D.Y. Heng, M.J. Mackenzie, and U.N. Vaishampayan Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy Ann Oncol 23 2012 1549 1555
29. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
30. E. Malle, S. Sodin-Semrl, and A. Kovacevic Serum amyloid A: an acute-phase protein involved in tumour pathogenesis Cell Mol Life Sci 66 2009 9 26
31. A. Ramankulov, M. Lein, and M. Johannsen Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma Cancer Lett 269 2008 85 92
32. M. Kimura, Y. Tomita, and T. Imai Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma Cancer 92 2001 2072 2075
33. B.L. Pierce, R. Ballard-Barbash, and L. Bernstein Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients J Clin Oncol 27 2009 3437 3444
34. S.L. Wood, M. Rogers, and D.A. Cairns Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer Br J Cancer 103 2010 101 111
35. P. Findeisen, M. Zapatka, and T. Peccerella Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling J Clin Oncol 27 2009 2199 2208
36. T. Yamada Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness Clin Chem Lab Med 37 1999 381 388
37. P.N. Manley, J.B. Ancsin, and R. Kisilevsky Rapid recycling of cholesterol: the joint biologic role of C-reactive protein and serum amyloid A Med Hypotheses 66 2006 784 792
38. J.G. Raynes, and E.H. Cooper Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease J Clin Pathol 36 1983 798 803